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Oral administration of cannabis 
with lipids leads to high levels 
of cannabinoids in the intestinal 
lymphatic system and prominent 
immunomodulation
Atheer Zgair1,2, Jong Bong Lee1, Jonathan C. M. Wong  1, Dhiaa A. Taha1, Jehan Aram3,  
Daisy Di Virgilio1, Joshua W. McArthur1, Yu-Kit Cheng1, Ivo M. Hennig4, David A. Barrett  1, 
Peter M. Fischer1, Cris S. Constantinescu3 & Pavel Gershkovich  1
Cannabidiol (CBD) and ∆9-tetrahydrocannabinol (THC) have well documented immunomodulatory 
effects in vitro, but not following oral administration in humans. Here we show that oral co-
administration of cannabinoids with lipids can substantially increase their intestinal lymphatic 
transport in rats. CBD concentrations in the lymph were 250-fold higher than in plasma, while THC 
concentrations in the lymph were 100-fold higher than in plasma. Since cannabinoids are currently in 
clinical use for the treatment of spasticity in multiple sclerosis (MS) patients and to alleviate nausea 
and vomiting associated with chemotherapy in cancer patients, lymphocytes from those patients were 
used to assess the immunomodulatory effects of cannabinoids. The levels of cannabinoids recovered in 
the intestinal lymphatic system, but not in plasma, were substantially above the immunomodulatory 
threshold in murine and human lymphocytes. CBD showed higher immunosuppressive effects than 
THC. Moreover, immune cells from MS patients were more susceptible to the immunosuppressive 
effects of cannabinoids than those from healthy volunteers or cancer patients. Therefore, administering 
cannabinoids with a high-fat meal or in lipid-based formulations has the potential to be a therapeutic 
approach to improve the treatment of MS, or indeed other autoimmune disorders. However, intestinal 
lymphatic transport of cannabinoids in immunocompromised patients requires caution.
Cannabis sativa has a very long history of medical use. It contains unique biochemical compounds called cannabi-
noids of which cannabidiol (CBD) and ∆9-tetrahydrocannabinol (THC) are the most abundant. Both compounds 
have been extensively studied over the last few decades for multiple therapeutic effects with immunomodulatory 
effects recently receiving considerable attention1,2. CBD has been shown to be effective following oral administration 
in lipid-based formulations or parenteral injections in animal models of a number of debilitating diseases caused by 
over-reactive immune responses (autoimmune and inflammatory diseases) including multiple sclerosis (MS)3, rheu-
matoid arthritis4, diabetes mellitus5, allergic asthma6, autoimmune hepatitis7 and colitis8. Similarly, THC has been 
shown to be beneficial following oral administration in lipid-based formulations or parenteral injections in MS9, 
diabetes mellitus10, and allergic asthma6 animal models. The proposed mechanisms governing these effects involve 
the ability of CBD and THC at relatively high concentrations to suppress lymphocyte proliferation and inflamma-
tory cytokine production3–8,11. This is supported by immunosuppressive effects that have been detected in in vitro 
studies12,13. Nevertheless, only a few human studies have been conducted to assess the immunomodulatory effects 
of cannabinoids in patients suffering from autoimmune diseases, particularly MS. These human studies showed no 
clear evidence for the immunosuppressive effects following oral administration of low-amount lipid-containing 
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formulations of cannabinoids14,15. In fact, Killestein et al.14 suggested a moderate pro-inflammatory potential in MS 
patients treated with orally administered cannabis extract. Katona et al.15 showed that the discrepancy between ani-
mal and human studies could be, in part, due to the high oral doses of cannabinoids used in animals (8–40 mg/kg) 
compared to around 0.25 mg/kg in human trials. This results in plasma levels in humans of approximately 5 ng/mL 
on average15. These low levels of cannabinoids detected in human plasma are consistent with the extensive first-pass 
metabolism reported for CBD and THC after oral administration16,17.
Recently, we have demonstrated that oral co-administration of CBD and THC with sufficient amount 
of long-chain triglycerides (LCT), equivalent to a moderate- to high-fat meal in man, can enhance intestinal 
lymphatic transport and markedly increase systemic bioavailability of cannabinoids in rats18. In addition, high 
concentrations within the intestinal lymphatic system have previously been reported for compounds which are 
absorbed following oral administration into systemic circulation primarily through the intestinal lymphatic sys-
tem19–21. Importantly, the intestinal lymphatic system is an essential contributor in the immune functions of the 
body22. It is the largest lymphatic organ and contains more than half of the body’s lymphocytes23,24. Therefore, 
the primary aim of our work was to assess whether the concentrations of CBD and THC found in the intestinal 
lymphatic system following oral co-administration with lipids could reach levels that are sufficiently high to pro-
duce immunomodulatory effects. MS and cancer patients on chemotherapy regimen were selected in this study 
as model cases of autoimmune illness and immunocompromised status, respectively, based on the fact that can-
nabinoids are currently used as symptomatic treatment in both patients groups25,26, and have immunomodulatory 
activity1. Therefore, an additional aim was to assess if such high levels in the intestinal lymphatic system are of 
potential therapeutic value to improve the treatment outcomes of autoimmune diseases such as MS, or can lead 
to potential safety considerations in immunocompromised patients such as those under chemotherapy regimens.
Results
Biodistribution of cannabinoids to rat mesenteric lymph nodes, spleen, lymph fluid and plasma 
following oral administration. The biodistribution of CBD and THC to mesenteric lymph nodes (MLN) 
was assessed following oral administration in lipid-free and LCT-based (solution in sesame oil) formulations to 
rats at the time of maximum concentration in plasma (tmax) and one-hour prior to tmax. These time points were 
based on our earlier study of the plasma pharmacokinetics of CBD and THC in rats (Supplementary Table S1)18. 
The concentrations of CBD and THC recovered in MLN following oral administration with LCT were profoundly 
higher than those observed after administration with lipid-free formulation at both time points (Fig. 1a,b). To 
assess the effect of intestinal lymphatic transport on the exposure of lymphocytes to cannabinoids within the 
intestinal lymphatic system versus splenocytes, the concentrations of cannabinoids in MLN were compared with 
those found in spleen. Figure 2a shows that significantly higher levels of cannabinoids were found in MLN com-
pared to spleen. The concentrations in MLN were more than 50-fold and 20-fold higher than in spleen for CBD 
and THC, respectively (Fig. 2a). Figure 2b shows the concentrations of CBD and THC in lymph fluid versus 
plasma. Profoundly higher concentrations of cannabinoids were observed in lymph fluid compared with plasma. 
CBD concentrations in intestinal lymph fluid were as much as 250-fold higher than the concentration in plasma, 
while the concentration of THC was 100-fold higher in lymph than in plasma.
Effect of CBD and THC on the proliferation of immune cells isolated from MLN and spleen 
of rats. Proliferation assays are commonly used to assess lymphocyte responses to a variety of stimuli27. 
We evaluated whether the concentration of cannabinoids achieved in the intestinal lymphatic system had 
Figure 1. Distribution of cannabinoids to mesenteric lymph nodes (MLN). Cannabinoids were orally 
administered in lipid-free and lipid-based formulations (solution of cannabinoids in sesame oil) to rats. (a) 
Concentration of CBD recovered in MLN at time of maximum concentration in plasma (tmax) and one-hour 
prior to tmax (tmax − 1 h) following oral administration of lipid-free formulation (12 mg/kg, n = 3 at tmax, n = 3 at 
tmax − 1 h), and long-chain triglycerides (LCT)-based formulation (12 mg/kg, n = 3 at tmax, n = 3 at tmax − 1 h) to 
rats. (b) Concentration of THC recovered in MLN at tmax and tmax − 1 h following oral administration of lipid-
free formulation (12 mg/kg, n = 5 at tmax, n = 4 at tmax − 1 h), and LCT-based formulation (12 mg/kg, n = 3 at 
tmax, n = 4 at tmax − 1 h) to rats. Values are expressed as mean ± SEM. Statistical analysis was performed using 
unpaired two-tailed Student’s t-test. *P < 0.05; **P < 0.01.
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immunomodulatory effects on immune cells isolated from MLN and the spleen of rats. CBD significantly sup-
pressed mitogen-stimulated proliferation of immune cells from both MLN and spleen at concentrations equal to 
and above 2.5 μg/mL (Fig. 3a,b). Slightly higher concentrations of THC were required to inhibit the proliferation 
of immune cells isolated from MLN and spleen, at and above 7.5 and 5 μg/mL, respectively (Fig. 3c,d).
CBD and THC attenuate the frequency of CD3+ T cells producing the pro-inflammatory 
cytokines, TNF-α and IFN-γ. In addition to lymphocyte proliferation, the immunomodulatory effects 
of CBD and THC were assessed by measuring the intracellular expression of TNF-α and IFN-γ in CD3+ T cells 
isolated from MLN and spleen of rats. As shown in Fig. 4A,B, CBD significantly decreased TNF-α expressing T 
cells from both MLN and spleen only at relatively high concentrations (20 μg/mL). However, a more potent effect 
was observed for CBD on IFN-γ (1 µg/mL). Similar to CBD, THC also significantly reduced TNF-α expressing T 
cells from MLN and spleen at the highest tested concentration of 20 μg/mL. However, lower concentrations were 
required to significantly reduce IFN-γ expressing T cells from MLN and spleen, at 5 and 1 μg/mL, respectively 
(Fig. 4C,D).
Effect of CBD and THC on the proliferation of peripheral blood mononuclear cells (PBMCs) iso-
lated from human blood. The immunomodulatory effects of CBD and THC were assessed on PBMCs 
isolated from human blood. Proliferation results showed that solutions of CBD and THC, as well as chylomicrons 
(CM)-associated CBD and THC can significantly inhibit the proliferation of PBMCs isolated from healthy vol-
unteers at concentrations equal to or above 5 and 10 μg/mL, respectively (Fig. 5a,b,e,f). To assess the potential 
therapeutic value of targeting lipophilic cannabinoids to the intestinal lymphatic system, the immunosuppressive 
effect of cannabinoids on PBMCs isolated from patients suffering from autoimmune disease, particularly MS 
patients (Table 1) was evaluated. In this patient group, CBD markedly suppressed the proliferation of PBMCs at 
half of the concentrations observed for healthy volunteers PBMCs (Fig. 5c). Similar results were also found for 
THC (Fig. 5g).
Furthermore, proliferation experiments were also conducted on PBMCs isolated from patients on chemo-
therapy regimens for treatment of non-seminomatous germ cell tumours (NSGCT, Table 2). In this set, CBD 
and THC showed anti-proliferative effects on PBMCs from NSGCT patients which were comparable to healthy 
volunteers, i.e. immunosuppressive effects at concentrations equal to and above 5 and 10 μg/mL, respectively 
(Fig. 5d,h).
Effects of CBD and THC on cytokine profiles of human lymphocytes. Following in vitro activa-
tion of PBMCs, the intracellular expression of TNF-α, IFN-γ, IL-2, IL-17A, and granulocyte-macrophage 
colony-stimulating factor (GM-CSF) was assessed by means of flow cytometry. Similar to the proliferation assay, 
PBMCs were isolated from healthy volunteers, MS patients, and NSGCT patients. In PBMCs of healthy volun-
teers, CBD only significantly decreased TNF-α, IFN-γ, and IL-17A expressing T cells when incubated with cells 
at the highest tested concentration (20 μg/mL). IL-2 and GM-CSF expressing T cells, however, were suppressed 
at CBD concentrations at and above 5 μg/mL (Fig. 6a). In the case of THC, no appreciable effect was observed on 
Figure 2. Concentration of cannabinoids recovered in spleen, mesenteric lymph nodes (MLN), plasma, 
and intestinal lymph fluid. Cannabinoids were orally administered in lipid-based formulations (solution of 
cannabinoids in sesame oil) to rats. (a) Concentration of CBD and THC in spleen (n = 6 and 3, respectively) and 
MLN (n = 3 and 4, respectively) two hours (one-hour prior to tmax) following oral administration of long-chain 
triglyceride (LCT)-based formulation (12 mg/kg) to rats. (b) Concentration of CBD and THC in plasma (n = 3 
and 4, respectively) and lymph (n = 3 and 4, respectively) two hours (one-hour prior to tmax) following oral 
administration of LCT-based formulation (12 mg/kg) to rats. Values are expressed as mean ± SEM. Statistical 
analysis was performed using unpaired two-tailed Student’s t-test. *P < 0.05; **P < 0.01; ****P < 0.0001.
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TNF-α, IFN-γ, and IL-17A expressing T cells compared to the vehicle-treated cells. However, IL-2 and GM-CSF 
expressing T cells were inhibited at concentrations equal to and above 5 μg/mL (Fig. 6d). For PBMCs isolated 
from MS patients, the immunosuppressive effects of CBD and THC on the expression of the tested cytokines 
were significantly higher compared to the effects on cells isolated from healthy volunteers (Fig. 6b,e). Moreover, 
the effects of CBD and THC on the expression of the assessed cytokines from NSGCT patient T cells were com-
parable to healthy volunteers cells with some exceptions (Fig. 6). These include more prominent immunosup-
pressive effects of CBD on TNF-α and IFN-γ expressing T cells as well as the effects of THC on TNF-α and IL-2 
expressing T cells from NSGCT patients (Fig. 6c,g). Representative flow cytometry histograms are shown in 
Supplementary Figure S1.
Discussion
Highly lipophilic drugs such as the phytocannabinoids CBD and THC are good candidates for intestinal lym-
phatic transport28. In light of this, we have recently shown that the systemic bioavailability of CBD and THC 
can be significantly enhanced when administered orally in conditions facilitating intestinal lymphatic transport, 
specifically co-administration with dietary lipids18. The results of the current study indicate that the intestinal 
lymphatic transport of CBD and THC in rats was, indeed, enhanced following oral co-administration of lipids 
as denoted by the dramatic increase in the concentrations recovered in MLN (Fig. 1a,b). More importantly, the 
biodistribution of CBD and THC to lymphoid tissues in the intestinal lymphatic system (MLN) was substantially 
higher than the distribution to the largest lymphatic tissue in the central compartment, the spleen (Fig. 2a). It is 
also important to note the extremely high concentration of cannabinoids recovered in intestinal lymph fluid com-
pared with plasma (Fig. 2b). Similar trends were previously reported for other lipophilic compounds, dexanabinol 
and PRS-211,220, when orally administered with LCT to rats19. Therefore, given our findings, we suggest that oral 
administration with dietary lipids has the potential to be an approach suitable for targeting delivery of CBD and 
THC to the intestinal lymphatic system. This targeting approach, as we have shown in our previous work, has the 
potential to increase the concentrations in plasma as well18.
The intestinal lymphatic system is the major host of immune cells. It has been proposed that the lymphatic 
system is an attractive target for immunomodulators whereby drugs can achieve high local concentrations and 
avoid systemic dilution28,29. This concept is supported by the fact that immune cells within the lymphatic system 
move more slowly and experience lower shear stress relative to those within the circulation30. In this study, the 
Figure 3. Effects of cannabinoids on the proliferation of immune cells isolated from mesenteric lymph nodes 
(MLN) and spleen of rats. Cells were stimulated by phytohaemagglutinin (PHA, 10 μg/mL) after incubation 
with CBD or THC at concentrations of 1–20 μg/mL. (a) Effect of CBD on the proliferation of immune cells 
isolated from MLN. (b) Effect of CBD on the proliferation of immune cells isolated from spleen. (c) Effect of 
THC on the proliferation of immune cells isolated from MLN. (d) Effect of THC on the proliferation of immune 
cells isolated from spleen. Values are expressed as percentage of absorbance compared to the control group of 
untreated cells, mean ± SEM (n = 5). Samples run in triplicates. Statistical analysis was performed using one-
way ANOVA with Fisher’s LSD test. Statistical differences compared to the vehicle (DMSO)-treated cells (VH); 
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
www.nature.com/scientificreports/
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effect of CBD and THC on the proliferation of immune cells isolated from lymphoid tissues in the intestinal 
lymphatic system and spleen of rats was assessed. Both cannabinoids significantly inhibited the proliferation of 
mitogen-stimulated immune cells from MLN and spleen at concentrations that are highly unlikely to be achieved 
in rat plasma, but can be easily obtained in the intestinal lymphatic system after co-administration of lipids 
(Fig. 3). In addition, the results suggest that CBD has more potent anti-proliferative effect than THC (Fig. 3). 
Moreover, in this study, CBD and THC attenuated the expression of TNF-α and IFN-γ, key pro-inflammatory 
cytokines in the pathogenesis of autoimmune diseases31, by CD3+ T cells isolated from MLN and spleen 
(Fig. 4). In line with the anti-proliferative effect, cannabinoids also suppressed the frequency of inflammatory 
cytokines-expressing T cells at micromolar concentrations, which are achievable in the intestinal lymphatic sys-
tem, but not in general circulation. To note, the reduced frequency of cytokines-expressing T cells can be poten-
tially due to a decrease in the proliferation of cells. The immunosuppressive effects of CBD and THC on murine 
immune cells in the same concentration range were also reported elsewhere12,32. Intestinal lymphatic transport 
could be a potential mechanism of previously reported therapeutic effects of CBD and THC in murine models of 
autoimmune diseases in which the cannabinoids were administered orally with substantial amounts of lipids3,10.
To assess the immunomodulatory effect of cannabinoids on human cells, proliferation assays were performed 
on PBMCs isolated from venous blood of human volunteers. Our results demonstrate that CBD and THC, at 
relatively high concentrations, inhibit the proliferation of mitogen-stimulated PBMCs isolated from healthy vol-
unteers (Fig. 5a,e). These results are consistent with previous reports13. Importantly, these concentrations would 
not be achievable in systemic blood circulation even if high oral doses of cannabinoids were consumed. Consroe 
et al.33 reported that the maximum plasma concentration recovered following repeated oral administration of 
10 mg/kg/day CBD (in a small-amount lipid-based formulation) in humans was 25 ng/mL. This is considerably 
lower than the 5 μg/mL concentration required to significantly inhibit PBMCs proliferation in this study (Fig. 5a). 
In contrast, high doses of THC are limited by the psychotropic side effects reported for this drug34. Nevertheless, 
given the results obtained in this study, it is likely that oral administration of CBD and THC in humans in con-
ditions facilitating intestinal lymphatic transport (with lipid dose in the range of 10 g35) can result in significant 
increases in intestinal lymphatic transport similar to what has been obtained for rats in this study. This is also sup-
ported by the fact that CBD and THC showed comparable association values with human and rat CM18. It should 
Figure 4. Effects of cannabinoids on the expression of inflammatory cytokines in immune cells isolated from 
rats. The figure shows the frequency of TNF-α and IFN-γ expressing CD3+ T cells isolated from mesenteric 
lymph nodes (MLN) and spleen of rats (% frequency of cytokines-expressing CD3+ T cells compared to 
the control group of untreated cells, mean ± SEM). Cells were stimulated by phorbol myristate acetate and 
ionomycin (PMA & I) in the presence of brefeldin A after incubation with CBD or THC at concentrations of 
1–20 μg/mL. (A) Effect of CBD on the frequency of cytokines-expressing CD3+ T cells isolated from MLN 
(n = 7). (B) Effect of CBD on the frequency of cytokines-expressing CD3+ T cells isolated from spleen (n = 5). 
(C) Effect of THC on the frequency of cytokines-expressing CD3+ T cells isolated from MLN (n = 7). (D) Effect 
of THC on the frequency of cytokines-expressing CD3+ T cells isolated from spleen (n = 5). Statistical analysis 
was performed using one-way ANOVA with Fisher’s LSD test. Statistical differences compared to the vehicle 
(DMSO)-treated cells (VH); *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
www.nature.com/scientificreports/
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be noted that CM association in the enterocytes is a prerequisite for the intestinal lymphatic delivery of lipophilic 
compounds when orally administered with lipids18,19,36,37. Importantly, in the current study, CM-associated can-
nabinoids were still able to inhibit the proliferation of PBMCs isolated from healthy volunteers, showing similar 
effects to cannabinoids in solution (Fig. 5b,f). Therefore, our results suggest that the fact that cannabinoids are 
delivered to the intestinal lymphatic system in a CM-associated form would not reduce the immunomodulatory 
effects. A possible explanation for this maintained effect in CM-associated form is that lymphocytes possess lipo-
protein lipase enzyme activity, which enables them to utilise fatty acids and triglycerides from CM38 and therefore 
to be exposed to cannabinoids.
In addition, our results indicate that PBMCs isolated from MS patients are more sensitive to the immunomod-
ulatory effects of cannabinoids compared to PBMCs isolated from healthy volunteers (Fig. 5c,g). This could be 
related to the up-regulation of cannabinoid CB2 receptors in the immune cells of MS patients39. These receptors 
are thought to be involved in the immunosuppressive effect of cannabinoids32,40. Interestingly, some other reports 
suggested that cannabinoids exert their immunosuppressive effect by CB2-independent mechanisms as well41. 
Another aspect demonstrated in this study is that cannabinoids have comparable anti-proliferative effects on 
PMBC isolated either from blood of cancer patients under chemotherapy regimens or from healthy volunteers 
(Fig. 5d,h). However, cancer patients on chemotherapy usually have low or low-borderline blood lymphocyte 
counts42, which was also the case in this study (Table 2). Therefore, there could be a potential effect of further 
immunosuppression in some people, such as cancer patients, when cannabinoids are administered in conditions 
that facilitate intestinal lymphatic transport.
It is widely accepted that TNF-α, IFN-γ, and IL-2 produced by TH1 cells are actively involved in the pathogen-
esis of many autoimmune diseases43. Recently, TH17 cells (which produce IL-17A) have emerged as a major factor 
in the pathogenesis of autoimmune diseases, as well as the contribution of GM-CSF to drive the inflammatory 
effects of TH1744 and TH145,46 cells. In this study, CBD and THC induced a profound decrease in the frequency of 
IL-2 and GM-CSF expressing T cells separated from healthy volunteers. This is consistent with the demonstration 
of a link between IL-2 production and GM-CSF induction47. CBD showed higher immunosuppressive effect than 
THC as manifested by the effect on TNF-α, IFN-γ, and IL-17A expressing T cells (Fig. 6a,d). For PBMCs isolated 
from MS patients, similar to the anti-proliferative effect, cannabinoids displayed more potent suppression of 
cytokine expression compared to cells from healthy volunteers (Fig. 6b,e). Yet, these effects were only observed 
at micromolar concentrations, consistent with previous reports13,48. Collectively, the effects of cannabinoids on 
lymphocyte proliferation and the frequency of cytokines-producing T cells explored in the current study suggest 
that targeting lipophilic cannabinoids to the intestinal lymphatic system for enhanced immunomodulatory effects 
Figure 5. Effects of cannabinoids on the proliferation of peripheral blood mononuclear cells (PBMCs) isolated 
from human participants. Cells were stimulated by phytohaemagglutinin (PHA, 10 μg/mL) after incubation 
with CBD or THC at concentrations of 1–20 μg/mL. (a) Effect of DMSO-dissolved CBD on PBMCs isolated 
from healthy volunteers (n = 4). (b) Effect of CM-associated CBD on PBMCs isolated from healthy volunteers 
(n = 3). (c) Effect of DMSO-dissolved CBD on PBMCs isolated from multiple sclerosis (MS) patients (n = 7, as 
indicated in Table 1).(d) Effect of DMSO-dissolved CBD on PBMCs isolated from patients on chemotherapy to 
treat non-seminomatous germ cell tumours (NSGCT) (n = 7). (e) Effect of DMSO-dissolved THC on PBMCs 
isolated from healthy volunteers (n = 4). (f) Effect of CM-associated THC on PBMCs isolated from healthy 
volunteers (n = 3). (g) Effect of DMSO-dissolved THC on PBMCs isolated from MS patients (n = 7, as indicated 
in Table 1). (h) Effect of DMSO-dissolved THC on PBMCs isolated from patients on chemotherapy to treat 
NSGCT (n = 7). Values are expressed as percentage of absorbance compared to the control group of untreated 
cells, mean ± SEM. Samples run in triplicates. Statistical analysis was performed using one-way ANOVA with 
Fisher’s LSD test. Statistical differences compared to the vehicle-treated cells (VH); *P < 0.05; **P < 0.01; 
***P < 0.001; ****P < 0.0001.
www.nature.com/scientificreports/
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in the treatment of autoimmune diseases could be a promising therapeutic approach. This approach could extend 
the therapeutic value of cannabinoids currently being used for symptomatic relief in MS patients25 to a disease 
modifying treatment, which could delay the progression of MS. Moreover, the results suggest that CBD has higher 
therapeutic effectiveness in autoimmune diseases compared with THC as it has more pronounced immunomod-
ulatory effects, is devoid of psychotropic side effects, and is well tolerated in humans following acute and chronic 
intake of relatively high doses49.
On the other hand, adequate levels of the above-mentioned cytokines are important to maintain adap-
tive immune responses to fight infections50,51. In this study, a substantial decrease in the frequency of 
cytokines-expressing T cells has been demonstrated with cannabinoids in PBMCs isolated from cancer patients 
under chemotherapy regimen (Fig. 6c,f). This can potentially further deteriorate chemotherapy-induced immu-
nosuppression in these patients. In addition, it has been reported that CBD and THC have inhibitory immuno-
modulatory effects on innate immune cells, particularly macrophages and natural killer cells (NK)52. It is well 
recognised that some cancer patients self-medicate and consume cannabis or cannabis-based medicinal formu-
lations orally to alleviate nausea and vomiting associated with chemotherapy26. Given the results of this study, in 
this patients group, oral administration of immunosuppressive drugs such as cannabinoids in conditions facili-
tating intestinal lymphatic transport requires caution.
In summary, it has been demonstrated in this work that oral co-administration of cannabis or cannabis-based 
medicines with lipids results in extremely high levels of lipophilic cannabinoids in the intestinal lymphatic sys-
tem and prominent immunomodulatory effects. Therefore, administering cannabinoids with a high-fat meal, 
as cannabis-containing food, or in lipid-based formulations has the potential to be a therapeutic approach to 
improve the treatment of MS, or indeed other autoimmune disorders. Whether cannabinoids as used in this 
study can also induce regulatory cytokines in addition to suppressing inflammatory ones as shown here remains 
Patient code Age (Y) Gender Type of MS EDSS Experiment
CMS-01 35 F RRMS 1.5 Lymphocyte proliferation assay
CMS-02 55 F RRMS 2.5 Lymphocyte proliferation assay
CMS-03 33 F RRMS 1.5 Lymphocyte proliferation assay
CMS-04 51 F RRMS 3 Lymphocyte proliferation assay
CMS-05 30 M RRMS 3 Lymphocyte proliferation assay
CMS-06 55 F RRMS 4 Lymphocyte proliferation assay
CMS-07 26 F RRMS 2.5 Lymphocyte proliferation assay
CMS-08 69 F SPMS* 6.5 Assessment of inflammatory cytokines
CMS-09 55 F RRMS 2.5 Assessment of inflammatory cytokines
CMS-10 33 F RRMS 2.5 Assessment of inflammatory cytokines
CMS-11 53 F RRMS 4.5 Assessment of inflammatory cytokines
CMS-12 74 F SPMS* 5.5 Assessment of inflammatory cytokines
CMS-13 30 F RRMS 2 Assessment of inflammatory cytokines
Table 1. List of multiple sclerosis (MS) patients whose blood samples were used for the assessment of 
immunomodulatory effects of CBD and THC. RRMS, relapsing-remitting MS; secondary-progressive MS; 
EDSS, Expanded Disability Status Scale. *Indicates secondary-progressive MS patients. All patients were not on 
disease modifying drugs (newly diagnosed patients or at least one month after the discontinuation of disease 
modifying drugs). All patients were known not to consume cannabinoids.
Patient code Age (y)
WBC 
(109/L) ANC (109/L) Ly (109/L)
CTC-01 35 1.1 0.1 0.8
CTC-02 59 2.2 0.5 1.4
CTC-03 21 2 0.5 1.2
CTC-04 21 6.4 3.8 1.7
CTC-05 36 2.9 0.4 1.2
CTC-06 43 4.3 1.5 2.2
CTC-07 29 6.1 3.6 1.7
CTC-08 46 11 9.7 0.9
CTC-09 18 2.4 1.1 0.9
CTC-10 38 10.3 6.3 2.7
Table 2. List of non-seminomatous germ cell tumour (NSGCT) patients whose blood samples were used for 
the assessment of immunomodulatory effect of CBD and THC. WBC, White Blood Cell Count; ANC, Absolute 
Neutrophil Count; Ly, Lymphocyte. Bloods were taken after a minimum of one cycle of chemotherapy at time of 
expected total white blood cell and neutrophil count recovery.
www.nature.com/scientificreports/
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to be determined. Further studies would be required to assess if both lymph and peripheral concentrations of 
cannabinoids have to be high for effective immunomodulation or only targeting to lymphatic system is sufficient. 
In addition, more work would have to be done to elucidate if cannabinoids could be used alone or as an adjuvant 
to other treatment. However, in immunocompromised patients, administration of cannabinoids in this way could 
potentially deepen the immunosuppressive effects. Further studies will be needed to evaluate the clinical signif-
icance of these effects.
Methods
Cannabinoids. CBD and THC were donated by GW Research Ltd (Cambridge, UK).
Animals. All experiments and procedures were approved by the UK Home Office in accordance with the 
Animals [Scientific Procedures] Act 1986. Experiments were performed using male Sprague-Dawley rats (Charles 
River Laboratories) weighing 300–349 g. The rats were housed in the University of Nottingham Bio Support Unit, 
and kept in a temperature-controlled and 12 hours light-dark cycle environment with free access to water and 
food. All experiments were performed in accordance with the approved guidelines.
Human samples. The protocol for the preparation of human plasma-derived CM emulsion was approved by 
the Faculty of Medicine and Health Sciences Research Ethics Committee, Queens Medical Centre, Nottingham 
University Hospitals, Nottingham, UK (BT12102015 CBS SoP). Lymphocyte proliferation and flow cytometry 
experiments conducted on PBMCs isolated from healthy volunteers and MS patients (Table 1) were approved 
by the Research Ethics Committee East Midlands – Nottingham 2, Nottingham, UK (08/H0408/167/AM05). 
Lymphocyte proliferation and flow cytometry experiments conducted on PBMCs isolated from NSGCT 
patients (Table 2) were approved by Nottingham Health Sciences Biobank at Nottingham University Hospitals, 
Nottingham, UK (ACP162). Informed written consent was obtained from all participants. The methods were 
carried out in accordance with the approved guidelines.
Figure 6. Effects of cannabinoids on the expression of inflammatory cytokines in CD3+ T cells isolated from 
human participants. Figure shows the frequency of TNF-α, IFN-γ, IL-2, IL-17A, and GM-CSF expressing 
CD3+ T cells isolated from human participants (% frequency of cytokines-expressing CD3+ T cells compared 
to the control group of untreated cells, mean ± SEM). Cells were stimulated by phorbol myristate acetate 
and ionomycin (PMA & I) in the presence of brefeldin A after incubation with cannabidiol (CBD) or 
∆9-tetrahydrocannabinol (THC) at concentrations of 1–20 μg/mL. (a) Effect of CBD on PBMCs from healthy 
volunteers (n = 5). (b) Effect of CBD on PBMCs from multiple sclerosis (MS) patients (n = 4, as indicated in 
Table 1).(c) Effect of CBD on PBMCs from patients on chemotherapy to treat non-seminomatous germ cell 
tumours (NSGCT) (n = 3). (d) Effect of THC on PBMCs from healthy volunteers (n = 5). (e) Effect of THC 
on PBMCs from MS patients (n = 3, as indicated in Table 1). (f) Effect of THC on PBMCs from patients on 
chemotherapy to treat NSGCT (n = 3). Statistical analysis was performed using one-way ANOVA with Fisher’s 
LSD test. The inset table in the lower left corner of each panel refers to the statistical differences compared to the 
vehicle (DMSO)-treated cells (VH). a, P < 0.05; b, P < 0.01; c, P < 0.001; d, P < 0.0001.
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Biodistribution of cannabinoids to MLN of rats. Following 5 days of acclimatisation, rats were fasted 
overnight with free access to water. Animals were orally administered CBD and THC in lipid-free (12 mg/mL 
solution in propylene glycol–ethanol–sterile water (80:10:10, v/v/v)) and LCT-based formulation (12 mg/mL 
solution in sesame oil) at a dose of 12 mg/kg. Rats were euthanised at the pre-determined time points of tmax and 
tmax − 1 h, time points are listed in Supplementary Table S1. MLN were then collected as previously described53. 
Briefly, animal carcass was laid on back and the ventral abdominal wall was incised to expose the intestine. MLN 
were removed from the mesenteric tissue in the abdominal cavity and placed in an Eppendorf tube. MLN were 
gently dissected from surrounding tissue, weighed, and homogenized with saline (1:3 w/v) on ice at 18,000 rpm 
for 3 min (POLYTRON® PT 10–35 GT, Kinematica AG, Luzern, Switzerland). Homogenates were then assessed 
for CBD and THC content as described in the analytical method section.
Biodistribution of cannabinoids to plasma, intestinal lymph fluid, and spleen of rats. Following 
5 days of acclimatisation, animals were fasted overnight with free access to water. CBD and THC were orally 
administered to rats in an LCT-based formulation (12 mg/kg). Animals were euthanized two hours following oral 
administrations. Blood samples were collected from the posterior vena cava. Lymph samples were collected from 
the mesenteric lymph duct. Briefly, the duct was ligated using 3–0 silk suture. A 25 G needle connected to 1 mL 
syringe was used to collect lymph form the duct (~50 µL of lymph was collected form each animal). In addition, 
spleen was collected, weighed, and homogenized as described above for MLN. Cannabinoids concentrations 
were then determined in plasma, intestinal lymph fluid, and spleen homogenates as described in the analytical 
method section.
Preparation of single-cell suspension from MLN and spleen of rats. Following 5 days of acclima-
tisation, animals were euthanized and the ventral abdominal wall was incised to expose the intestine. MLN and 
spleen were aseptically collected. MLN were gently dissected from surrounding tissue and spleen was scored with 
a clean scalpel before being mashed on cell strainer (70 μm Nylon, Corning Falcon™). Red blood cells in the cell 
suspension of the splenocytes were lysed by lysing buffer (BD Bioscience). Immune cells from MLN and spleno-
cytes were then washed twice with PBS. Cell suspension was centrifuged (400 g, 5 min at room temperature) and 
resuspended in complete RMPI-1640 culture medium (RMPI-1640 culture medium with L-glutamine supple-
mented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin, all purchased from Sigma Aldrich) 
at concentration of 1.2 × 106 cells/mL to be used for proliferation and flow cytometry experiments.
Isolation of PBMCs from human blood. PBMCs were obtained from heparinised venous blood of 
healthy adult volunteers, MS patients (eleven relapsing-remitting and two secondary-progressive MS patients, 
Table 1), and NSGCT patients (Table 2) by density centrifugation (800 g, 30 min, 20 °C) using Histopaque®−1077 
(Sigma Aldrich). Cells were suspended in complete RMPI-1640 culture medium at concentrations of 7.5 × 105 
and 1 × 106 cells/mL for lymphocyte proliferation assay and flow cytometry experiments, respectively.
Preparation of human CM-associated CBD and THC. Human plasma-derived CM emulsion was pre-
pared from three male healthy human volunteers as previously described18. The uptake of CBD and THC by 
human CM emulsion was performed as previously described with small modifications36. Briefly, stock solutions 
of CBD and THC (12 mg/mL) were prepared in propylene glycol–ethanol (90:10, v/v). A volume of 25 µL of can-
nabinoid stock solution was added to 2 mL of the CM emulsion and incubated at 37 °C for 1 hour with continuous 
mixing. Following incubation, the density of the emulsion was adjusted to 1.1 g/mL using potassium bromide 
(Sigma Aldrich). CM were then separated by density gradient ultracentrifugation (SORVALL® TH-641 Rotor, 
Thermo Fisher Scientific, 268,350 g, 35 min, 15 °C). The top 1 mL layer was collected following ultracentrifuga-
tion using a glass pipette. The concentration of CBD and THC in CM emulsion was assessed as described in the 
analytical methods section below. CM-associated cannabinoids were kept at 4 °C pending proliferation assay 
experiments (<24 hours).
Lymphocyte proliferation assay. Immune cells from rats (MLN and spleen cells) and PBMCs from 
human participants were cultured in flat clear-bottom 96-well microplates (Thermo Scientific Nunc®) at concen-
tration of 8.4 × 104 and 5.2 × 104 cells/well, respectively. Working stock solutions of CBD and THC in RMPI-1640 
culture medium-DMSO (99:1, v/v) were prepared at concentrations of 10, 25, 50, 75, 100, 150, and 200 μg/mL. 
Working stock solutions of CM-associated cannabinoids were also prepared at the same aforementioned concen-
trations. Cannabinoids were incubated with cells at final concentrations of 1, 2.5, 5, 7.5, 10, 15, and 20 μg/mL in a 
humidified atmosphere of 5% CO2 at 37 °C for 30 min. Cells were then stimulated by the T cell-selective mitogen 
Phytohaemagglutinin54 (PHA, 10 μg/mL, Sigma Aldrich) and incubated in a humidified atmosphere of 5% CO2 
at 37 °C for 2 days. Cell proliferation was assessed by enzyme-linked immunosorbent assay (ELISA) based on 
bromo-2′-deoxyuridine (BrdU) incorporation into newly synthetised DNA according to the manufacturer pro-
tocol (Roche Applied Science, Roche Diagnostics Ltd, UK). Finally, the absorbance of these wells was observed at 
370 nm, with reference wavelength at 492 nm using plate reader (EnVision® Multilabel Plate Reader, PerkinElmer 
Inc., USA). Absorbance values were normalised to the absorbance of culture medium-treated cells.
Flow cytometry analysis. Freshly isolated immune cells of MLN and splenocytes from rats and thawed 
PBMCs from human participants were incubated with CBD or THC (1–20 μg/mL) for 30 min in FACS tubes. 
Cells were then stimulated with phorbol myristate acetate and ionomycin (PMA & I) in the presence of brefeldin 
A and incubated in a humidified atmosphere of 5% CO2 at 37 °C for 5 hours. After stimulation, cells were washed 
with PBS and centrifuged to pellet (290 g, 5 min, 20 °C). Cell pellet was resuspended and labelled with Zombie 
UV™ Fixable Viability kit according to the manufacturer’s protocol (Biolegend) for the purpose of excluding 
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dead cells during the analysis of data (the effect of cannabinoids on the variability of immune cells isolated from 
healthy volunteers is presented in Supplementary Figure S2). Fixation and permeabilization was performed using 
BD Cytofix/Cytoperm™ kit according to the manufacturer’s protocol (BD Bioscience). Rat’s immune cells were 
labelled with APC anti-rat CD3, PE anti-mouse / rat TNF-α, and FITC anti-rat IFN-γ antibodies (Biolegend). 
Human’s PBMCs were labelled with BV421 anti-human TNF-α and PerCP/Cy5.5 anti-human IL-2 antibodies 
(Biolegend), ECD anti-human CD3, FITC anti-human IFN-γ antibodies (Beckman Coulter), and PE anti-human 
IL-17A, and APC anti-human GM-CSF antibodies (eBioscience). Isotype and fluorescence minus one (FMO) 
controls were prepared for all antibodies in each flow cytometry run. Data were collected on MoFlo® Astrios™ 
EQ flow cytometer and analysed using Kaluza analysis software v 1.5 (Beckman Coulter). The gating strategy used 
for data analysis is illustrated in Supplementary Figure S3.
Analytical methods. The concentrations of CBD in rat plasma, intestinal lymph fluid, MLN homogenates, 
spleen homogenates, and human CM samples, as well as THC concentrations in rat plasma, intestinal lymph 
fluid, and human CM samples were determined using HPLC system (Waters Alliance 2695 separations module) 
equipped with photodiode array ultraviolet (UV) detector (Waters 996)18,55. Concentrations of THC in MLN 
and spleen homogenates were determined by LC-MS/MS system consisted of Quattro Ultima triple-quadrupole 
mass spectrometer (Waters) coupled with Agilent HPLC system (1100 Series, Agilent Technologies) as previously 
described for the detection of THC in microsomal samples56. Chromatographic conditions for the detection of 
CBD and THC in rat plasma, intestinal lymph fluid, MLN homogenates, spleen homogenates, and human CM 
samples are summarized in Supplementary Table S2.
Statistical analysis. Results are expressed as mean ± standard error of the mean (SEM). Statistical differ-
ences between data sets were assessed using either ANOVA with Fisher’s LSD test or unpaired two-tailed Student’s 
t-test, as appropriate. A P value < 0.05 was considered to represent a significant difference.
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